ArticleArchives of microbiology2026
Morpho-molecular approach reveals a myco-endophyte, Aspergillus novoparasiticus CBS126849 (MTCC-13997) from the roots of Capparis decidua with therapeutic and enzymatic potential.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Endophytic fungi inhabit plants asymptomatically and produce host-like bioactive metabolites. This study reports the isolation and identification of the endophytic fungus Aspergillus novoparasiticus CBS126849 (MTCC-13997) from the roots of Capparis decidua ("Ker/Kair"), highlighting its potential as a source of bioactive compounds and enzymes. The isolate was recognized based on phylogenetic analysis of the ITS sequence and morphological features. A. novoparasiticus (MTCC-13997) ethyl acetate crude extract (An-EtOAcE) exhibited notable antimicrobial, antioxidant, antidiabetic, cytotoxic, and extracellular enzymatic activities. The results revealed that An-EtOAcE exhibited broad-spectrum antimicrobial effects, with maximum inhibition against E. coli (MIC = 0.78 µg/mL) and A. niger (MIC = 3.125 µg/mL). It also showed notable antioxidant activities in both DPPH (IC
Indexed as
Identifiers
42631714What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.